Icecure Medical Ltd(ICCM) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -6.57 | Insider Own | 67.88% | Shs Outstand | 3.4M | Perf Week | -5.31% |
| Market Cap | 0.01B | Forward P/E | - | EPS next Y | 31.59% | Insider Trans | - | Shs Float | 1.1M | Perf Month | -39.03% |
| Enterprise Value | -0.00B | PEG | - | EPS next Q | -1.16 | Inst Own | 12.6% | Short Float | 3.71% | Perf Quarter | -15.75% |
| Income | -0.02B | P/S | 1.86 | EPS this Y | 25.69% | Inst Trans | 6.95% | Short Ratio | 0.01 | Perf Half Y | -89.34% |
| Sales | 0.00B | P/B | 0.62 | EPS next 5Y | 32.04% | ROA | -119.31% | Short Interest | 0.04M | Perf YTD | -88.31% |
| Book/sh | 3.47 | P/C | 0.61 | EPS past 3/5Y | 19.27% 32.65% | ROE | -228.31% | 52W High | -94.9% ($42.00) | Perf Year | -92.87% |
| Cash/sh | 3.51 | P/FCF | - | Sales past 3/5Y | 3.08% -2.67% | ROIC | -141.65% | 52W Low | 1.9% ($2.10) | Perf 3Y | -93.33% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 20.47% | Gross Margin | 36.1% | Volatility(W/M) | 5.38% 8.13% | Perf 5Y | -99.29% |
| Dividend TTM | - | EV/Sales | -1.17 | Sales Y/Y TTM | 41.62% | Oper. Margin | -423.69% | ATR (14) | 0.23 | Perf 10Y | -95.45% |
| Dividend Ex-Date | - | Quick Ratio | 2.44 | EPS Q/Q | 22.14% | Profit Margin | -427.67% | RSI (14) | 31.18 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.87 | Sales Q/Q | 72.76% | SMA20 | -10.8% ($2.4) | Beta | 0.4 | Target Price | $19 |
| Payout | - | Debt/Eq | 0.01 | Earnings | 2026/8/12 | SMA50 | -30.03% ($3.06) | Rel Volume | 0.08 | Prev Close | $2.11 |
| Employees | 69 | LT Debt/Eq | 0 | EPS/Sales Surpr. | -1.87% -37.46% | SMA200 | -81.08% ($11.31) | Avg Volume(3M) | 3.31M | Price | $2.14 |
| IPO | 2013/11/7 | Option/Short | No/Yes | Trades | 714 | Volume | 273,284 | Change | 1.42% |
Company
ICCM is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
A medical device company specializing in cryoablation, a treatment that destroys tumors by freezing them. Its core product, ProSense, is an FDA-approved device that treats breast and kidney cancer tumors without surgery. It uses liquid nitrogen to generate ultra-low temperatures below -170°C to eliminate tumors, and the company is headquartered in Israel.
Over the past 1 year, on the lower side
95% below its 1-year high.
ICCM has weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +25.7% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by -93.3% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 12.6%.
Tap to view numbers
It ranks #4 in the industry
Based on market cap of $7M.
ICCM $7M PER -
ABT $179B PER 33.4
MDT $117B PER 22.6
SYK $104B PER 28.0
FAQ
What kind of company is ICCM?
ICCM belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of ICCM?
The market cap of ICCM is approximately $7M, ranking 5,588 within its sector.
What is the 52-week high and low for ICCM?
ICCM has recorded a 52-week high of $42.00 and a low of $2.10.
